2+ breast cancer. The aim is to assess the cost-effectiveness of adding pertuzumab to the combination of trastuzumab …, the addition of pertuzumab does not result in significantly longer patients' survival. Since the treatment is associated … with higher costs, adding pertuzumab is not considered to be cost-effective; however, this could be due to relatively short …

-effectiveness of adding pertuzumab in neoadjuvant treatment (NeoT) for HER2-positive breast cancer (BC). Methods: Two retrospective …Background: Breast cancer (BC) is largely prevalent worldwide. HER2-positive BC account for roughly 20-25% of all BC … also pertuzumab as NeoT. NeoT was followed by surgery and adjuvant trastuzumab. Micro-costing technique and a bottom …

Introduction: Persistent infections with human papillomavirus (HPV) are a necessary cause of cervical cancer and are … was used to compare a cervical cancer screening only strategy with a strategy of combining vaccination of females aged 12 …–17 years old and cervical cancer screening, based on the current recommendations in Germany. In addition, the impact of …